For research purposes, the practical use cases are: GLP-1 plateau rescue adding cagrilintide to a stalled semaglutide or tirzepatide protocol GLP-1 dose reduction using cagrilintide to maintain weight loss while tapering GLP-1 Standalone titration cagrilintide at 2.4 mg/week produced ~8-10% weight loss in monotherapy trials But here's the synthesis problem: cagrilintide has the same lipid-conjugation chemistry as semaglutide
Because of its role in cellular energy, NAD+ IV therapy has been explored for benefits such as improved cognitive function, reduced fatigue, and potential anti-aging effects
Another trial in 115 heart attack patients found 1.8 grams EPA daily for one month, beginning one day after the heart attack, reduced the likelihood of ventricular arrhythmia: the incidence of ventricular arrhythmia was 7.0% in the EPA group and 20.6% in the control group (Doi 2014)
Class Side Effects: Decreased Pressure in the Lower Oesophageal and the Pyloric Sphincters After the Administration of Dopamine Antagonists, Neuroleptics, Anti-emetics, L-NAME, Pentadecapeptide BPC 157 and L-Arginine
Li Y, Soendergaard C, Bergenheim FH, Aronoff DM, Milne G, Riis LB, et al
Ubiquinol-10 delays postovulatory oocyte aging by improving mitochondrial renewal in pigs